Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome

Arthritis Research and Therapy

Volumn 11, Issue 6, 2009, Pages

  Vosters, Jelle L ^a,b   Yin, Hongen ^a   Roescher, Nienke ^a,b   Kok, Marc R ^a,b   Tak, Paul P ^b   Chiorini, John A ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CANCER GROWTH FACTOR; CYTOKINE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; PILOCARPINE; TUMOR GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EMBRYO; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SALIVARY GLAND; SALIVARY GLAND DISEASE; SALIVARY GLAND FUNCTION; SALIVATION; SJOEGREN SYNDROME; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GENE THERAPY; GENE TRANSFER; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; NONOBESE DIABETIC MOUSE; PATHOLOGY;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED NOD; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 77952479691     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2888     Document Type: Article

References (45)

1. Fox RI. Sjogren's syndrome. Lancet 2005, 366:321-331. 10.1016/S0140-6736(05)66990-5, 16039337.
2. Van Mello NM, Pillemer SR, Tak PP, Sankar V. B cell MALT lymphoma diagnosed by labial minor salivary gland biopsy in patients screened for Sjogren's syndrome. Ann Rheum Dis 2005, 64:471-473. 10.1136/ard.2004.022707, 1755410, 15708896.
3. Taylor PC. Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern Med 2003, 42:15-20. 10.2169/internalmedicine.42.15, 12583612.
4. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279. 10.1016/j.pharmthera.2007.10.001, 18155297.
5. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002, 2:37-45. 10.1038/nri702, 11905836.
6. Garcic-Carrasco M, Font J, Filella X, Cervera R, Ramos-Casals M, Siso A, Aymami A, Ballesta AM, Ingelmo M. Circulating levels of Th1/Th2 cytokines in patients with primary Sjogren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001, 19:411-415.
7. Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 1994, 152:5532-5539.
8. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puechal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004, 50:1270-1276. 10.1002/art.20146, 15077311.
9. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis Rheum 2002, 46:3301-3303. 10.1002/art.10674, 12483735.
10. Wu AJ, Hua H, Munson SH, McDevitt HO. Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci USA 2002, 99:12287-12292. 10.1073/pnas.172382999, 129437, 12221281.
11. Kodama S, Davis M, Faustman DL. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell Mol Life Sci 2005, 62:1850-1862. 10.1007/s00018-005-5022-6, 15968469.
12. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004, 50:2240-2245. 10.1002/art.20299, 15248223.
13. Moutsopoulos NM, Katsifis GE, Angelov N, Leakan RA, Sankar V, Pillemer S, Wahl SM. Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 2008, 67:1437-1443. 10.1136/ard.2007.077891, 18198195.
14. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 2007, 56:3995-4004. 10.1002/art.23062, 2737264, 18050196.
15. Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsutsui MT, Tak PP, Chiorini JA, Baum BJ. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndrome. Hum Gene Ther 2003, 14:1605-1618. 10.1089/104303403322542257, 14633403.
16. Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP, Baum BJ. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006, 65:195-200. 10.1136/ard.2005.038232, 1798026, 15975969.
17. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001, 75:6884-6893. 10.1128/JVI.75.15.6884-6893.2001, 114416, 11435568.
18. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991, 174:1483-1489. 10.1084/jem.174.6.1483, 2119031, 1660525.
19. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986, 95:99-105. 10.1016/0022-1759(86)90322-4, 3782828.
20. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998, 9:2745-2760. 10.1089/hum.1998.9.18-2745, 9874273.
21. Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated Defective Virus Particles. Science 1965, 149:754-756. 10.1126/science.149.3685.754, 14325163.
22. Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, Tak PP. Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther 2005, 7:R862-867. 10.1186/ar1757, 1175038, 15987488.
23. Khoury M, Adriaansen J, Vervoordeldonk MJ, Gould D, Chernajovsky Y, Bigey P, Bloquel C, Scherman D, Tak PP, Jorgensen C, Apparailly F. Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J Gene Med 2007, 9:596-604. 10.1002/jgm.1053, 17514770.
24. Adriaansen J, Khoury M, de Cortie CJ, Fallaux FJ, Bigey P, Scherman D, Gould DJ, Chernajovsky Y, Apparailly F, Jorgensen C, Vervoordeldonk MJ, Tak PP. Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis 2007, 66:1143-1150. 10.1136/ard.2006.064519, 17363402.
25. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974, 37:217-229. 10.1016/0030-4220(74)90417-4, 4589360.
26. Nguyen CQ, Cha SR, Peck AB. Sjogren's syndrome (SjS)-like disease of mice: the importance of B lymphocytes and autoantibodies. Front Biosci 2007, 12:1767-1789. 10.2741/2187, 17127420.
27. De Rycke L, Baeten D, Kruithof E, Bosch F, Veys EM, De Keyser F. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005, 14:931-937. 10.1191/0961203305lu2240rr, 16425572.
28. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008, 10:202. 10.1186/ar2341, 2374473, 18226185.
29. Masli S, Turpie B. Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells. Immunology 2009, 127:62-72. 10.1111/j.1365-2567.2008.02933.x, 18795974.
30. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009, 175:1167-1177. 10.2353/ajpath.2009.090319, 19700754.
31. Vosters JL, Landek-Salgado MA, Yin H, Swaim WD, Kimura H, Tak PP, Caturegli P, Chiorini JA. Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome. Arthritis Rheum 2009, 60:3633-3641. 10.1002/art.24980, 19950301.
32. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N. SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol 1995, 155:3205-3212.
33. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001, 57:1885-1888.
34. Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 2005, 39:303-306. 10.1097/01.mcg.0000155126.82171.32, 15758624.
35. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003, 30:2287-2291.
36. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86:242-251. 10.1097/MD.0b013e3181441a68, 17632266.
37. Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K. Impaired salivary gland function in NOD mice: Association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum 2006, 54:2300-2305. 10.1002/art.21945, 16802370.
38. Lodde BM, Mineshiba F, Kok MR, Wang J, Zheng C, Schmidt M, Cotrim AP, Kriete M, Tak PP, Baum BJ. NOD mouse model for Sjogren's syndrome: lack of longitudinal stability. Oral Dis 2006, 12:566-572. 10.1111/j.1601-0825.2006.01241.x, 17054769.
39. Saravia-Fernandez F, Durant S, Hasnaoui A, et al. Environmental and Experimental Procedures Leading to Variations in the Incidence of Diabetes in the Nonobese Diabetic (NOD) Mouse. Autoimmunity 1996, 24:113-121. 10.3109/08916939609001952, 8986323.
40. Soyfoo MS, De Vriese C, Debaix H, Martin-Martinez MD, Mathieu C, Devuyst O, Steinfeld SD, Delporte C. Modified aquaporin 5 expression and distribution in submandibular glands from NOD mice displaying autoimmune exocrinopathy. Arthritis Rheum 2007, 56:2566-2574. 10.1002/art.22826, 17665453.
41. Nguyen C, Cornelius J, Singson E, Killedar S, Cha S, Peck AB. Role of complement and B lymphocytes in Sjogren's syndrome-like autoimmune exocrinopathy of NOD.B10-H2b mice. Mol Immunol 2006, 43:1332-1339. 10.1016/j.molimm.2005.09.003, 16221495.
42. Nguyen CQ, Kim H, Cornelius JG, Peck AB. Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3. J Immunol 2007, 179:2318-2329.
43. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, McDevitt HO. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994, 180:995-1004. 10.1084/jem.180.3.995, 2191653, 8064245.
44. McDevitt H, Munson S, Ettinger R, Wu A. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 2002, 4(Suppl 3):S141-152. 10.1186/ar570, 12110133.
45. Hunger RE, Carnaud C, Garcia I, Vassalli P, Mueller C. Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55. Eur J Immunol 1997, 27:255-261. 10.1002/eji.1830270138, 9022027.